(Q40361106)

19 September 2017

title

The inhibitory effects of anticoagulation on in vivo gene transfer by adeno-associated viral or adenoviral vectors (English)

1 reference

19 September 2017

1 reference

1 reference

Joerg Schuettrumpf

1

1 reference

19 September 2017

Jianxiang Zou

2

1 reference

19 September 2017

Yi Zhang

3

1 reference

19 September 2017

Alexander Schlachterman

4

1 reference

19 September 2017

Yi-Lin Liu

5

1 reference

19 September 2017

Shyrie Edmonson

6

1 reference

19 September 2017

Weidong Xiao

7

1 reference

19 September 2017

Valder R Arruda

8

1 reference

19 September 2017

publication date

17 October 2005

1 reference

19 September 2017

1 reference

19 September 2017

volume

13

1 reference

19 September 2017

issue

1

1 reference

19 September 2017

page(s)

88-97

1 reference

Human gene therapy: the good, the bad, and the ugly

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Gene transfer as a tool to induce therapeutic vascular growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Clinical gene transfer studies for hemophilia B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

7 January 2021

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Selective inhibition of the prothrombinase complex: factor Va alters macromolecular recognition of a tick anticoagulant peptide mutant by factor Xa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Anticoagulant effects of the selective factor XA inhibitors tick anticoagulant peptide and antistasin in the APTT assay are determined by the relative rate of prothrombinase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

The kinetics of rAAV integration in the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Identification of PDGFR as a receptor for AAV-5 transduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Successful expression of human factor IX following repeat administration of adenoviral vector in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Mutation in blood coagulation factor V associated with resistance to activated protein C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Factor V: a combination of Dr Jekyll and Mr Hyde

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Low-molecular-weight heparins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Thrombin signalling and protease-activated receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Generation and characterization of chimeric recombinant AAV vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

7 January 2021

Myocardial gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Stability of adenoviral vectors following catheter delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Biocompatibility of cardiovascular gene delivery catheters with adenovirus vectors: an important determinant of the efficiency of cardiovascular gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Factor IX variants improve gene therapy efficacy for hemophilia B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.08.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2005.08.004

1 reference

19 September 2017

1 reference